OriCell Therapeutics
Aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.
Launch date
Employees
Market cap
-
Enterprise valuation
€545m (Public information from Feb 2023)
China (HQ)